Quotient Wealth Partners LLC Has $773,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Quotient Wealth Partners LLC lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 6.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,985 shares of the company’s stock after selling 599 shares during the period. Quotient Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $773,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of NVO. Daiwa Securities Group Inc. acquired a new position in shares of Novo Nordisk A/S in the third quarter valued at approximately $28,000. Capital Performance Advisors LLP acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at $42,000. Albion Financial Group UT increased its position in Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after buying an additional 278 shares during the period. Sound Income Strategies LLC lifted its holdings in shares of Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after buying an additional 243 shares in the last quarter. Finally, Hager Investment Management Services LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $46,000. 11.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on NVO shares. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets decreased their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Trading Down 0.9 %

Shares of NVO opened at $86.39 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.75 and a current ratio of 0.74. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The firm has a market cap of $387.66 billion, a price-to-earnings ratio of 26.26, a PEG ratio of 0.96 and a beta of 0.45. The business’s fifty day moving average is $91.46 and its 200-day moving average is $111.51.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts anticipate that Novo Nordisk A/S will post 3.86 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. The ex-dividend date is Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is presently 21.88%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.